Abstract
The inflammasome is a multimeric protein complex located in the cytoplasm that is activated by many factors and subsequently promotes the release of proinflammatory factors such as interleukin (IL)-1β and IL-18, resulting in a series of inflammatory responses that ultimately lead to the occurrence of various diseases. The Nod-like receptor protein 3 (NLRP3) inflammasome is the most characteristic type and the most widely studied among many inflammasomes. Activation of the NLRP3 inflammasome is closely related to the occurrence of many diseases, such as Alzheimer's disease. At present, a large number of studies have focused on the mechanisms underlying the activation of the NLRP3 inflammasome. Plenty of articles have reported the activation of the NLRP3 inflammasome by various ions, such as K+ and Na+ reflux and Ca2+ influx. However, few articles have reviewed the effects of various ion channels on the activation of the NLRP3 inflammasome and the relationship between the diseases caused by these proteins. This article mainly summarizes the relationship between intracellular and extracellular ion activities and ion channels and the activation of the NLRP3 inflammasome. We also provide a general summary of the diseases of each system caused by NLRP3 activation. We hope that more research will provide options for the treatment of diseases driven by the NLRP3 inflammasome.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
InflammasomeS are multimeric protein complexes that were first proposed by Jurg Tcholop in 2002, are assembled by intracytoplasmic pattern recognition receptors and are an important component of innate immunity [1]. The assembly of the inflammasome occurs in many cells, such as macrophages, dendritic cells, neutrophils and epithelial cells [2]. When the body is invaded by pathogenic microorganisms or injured by endogenous danger signals, pattern-recognition receptors (PRRs) recognize pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs), induce the assembly of the inflammasome, and promote the release of the proinflammatory cytokines interleukin (IL)-1β and IL-18, the occurrence of an immune response and pyroptosis, which exerts significant positive effects on immune defenses against bacteria and viruses and the repair of damaged tissues. However, an increasing number of studies have suggested that inflammasome activation is closely related to many diseases [3,4,5]. Inflammasomes are classified according to the subcellular localization of the PRR. Nucleotide-binding and oligomerization domain Nod-like receptors, RIG-I-like receptors and AIM2-like receptors are located inside cells, and Toll-like receptors and C-type lectin receptors are located in the plasma membrane and endosome [6]. At present, many inflammasomes are known, but the most powerful and the most extensively studied inflammasome is the Nod-like receptor protein 3 (NLRP3) inflammasome; therefore, we chose it for this review.
The NLRP3 inflammasome belongs to the NLR protein family and is the most characteristic member. NLRP3 is composed of an N-terminal pyrin domain, a central nucleotide-binding domain and a C-terminal leucine-rich repeat domain [7]. The assembly of the NLRP3 inflammasome includes upstream sensor proteins (NOD-like receptors), adaptor proteins, apoptosis-related speck-like proteins, including apoptosis-associated speck-like protein containing a caspase recruit domain (ASC), and the downstream effector protein caspase-1[8]. Abnormal activation of the NLRP3 inflammasome is closely related to the occurrence and development of different diseases in various systems, such as Alzheimer's disease, coronary atherosclerosis and diabetes [9]. Increasingly, some ion-related cellular events have been shown to play an important role in the activation of the NLRP3 inflammasome, such as K+ and Cl− efflux, Ca2+ mobilization, Na+ influx, and intracellular acidification [10, 11]. Although NLRP3 has been studied in many systems and many related reviews have been published, NLRP3-activated ion signaling requires greater work to refine and a detailed overview of the relationship between NLRP3 and intracellular and extracellular ions, ion channels, and diseases is currently unavailable. Hence, we will focus on this topic in our review. This review is expected to provide new targets for or insights into the study on the pathogenic mechanism of NLRP3 and treatment of NLRP3-related diseases.
Cellular events related to NLRP3 activation
The recognized signaling pathways of inflammasomes
The activation of NLRP3 inflammasome is divided into canonical activation pathway and non-canonical activation pathway. The initiation signal is usually recognized by Toll-like receptor (TLRs) ligands for some microbial molecules or by some cytokine ligands, and promotes the transcription of inflammasome-related components through the activation of nuclear factor-kappa B (NF-κB) and the post-translational modification of the NLRP3 inflammasome. [12]. DAMPs and PAMPs are the activation signals that trigger NLRP3 activation, and these components include extracellular ATP, bacterial pore-forming toxins, melanocin, and particulate matter (uric acid crystals, silica, etc.) [13]. The assembly of the inflammasome is through the interaction between the pyrin domain (PYD) of the ASC and the PYD of the NLR to recruit ASC to form ASC spots, which are then recruited through the caspase-activation and recruitment domain CARD-CARD interaction. Then, CARD domain in turn recruits the CARD of procaspase-1. Pro-caspase-1 clustering permits autocleavage and formation of the active caspase-1 p20/p10 tetramer, which promotes cleavage and maturation of downstream cytokines IL-1β and IL-18, ultimately they lead to a series of inflammatory responses [14, 15]. Besides, active caspase-1 can also cleavage of gasdermin D (GSDMD) induces pyroptosis, a novel form of cell death [4, 16]. On the other hand, in the non-canonical activation pathway of the NLRP3 inflammasome, lipopolysaccharide (LPS) secreted by Gram-negative bacteria can promote GSDMD cleavage by interacting with caspase-4/5/11, thereby inducing pyroptosis [17, 18] (Fig. 1). Furthermore, caspase-4/5/11 can activate NLRP3 by activating an ATP-gated cation-selective channel that can open to trigger K+ efflux [19] (Fig. 2). In addition, in human monocytes, LPS can recognize TLR4 to activate NLRP3 through the TLR4-TRIF-RIPK1-FADD-CASP8 signaling pathway, termed the alternative activation pathway of NLRP3 (Fig. 2) [20].
Ion regulatory mechanism during NLRP3 activation
K+ efflux is a recognized upstream signal of NLRP3 activation
Studies have shown that a decrease in intracellular K+ levels is an important stimulus that activates NLRP3 through a mechanism induced by ATP and other DAMPs [21, 22]. V P E´trilli et al. found that high extracellular potassium levels inhibit the activation of NLRP3 in human monocytes and that a decreased intracellular potassium concentration triggers the activation of the NLRP3 inflammasome [23]. Raúl Muñoz-Planillo and other scholars aimed to further determine the role of K+ efflux in the activation of the NLRP3 inflammasome and proved that the activation of the NLRP3 inflammasome causes a decrease in intracellular K+ concentration. They also found that ASC oligomerization, also called ASC aggregation into ASC speck macromolecules during inflammasome activation, is suppressed by high extracellular K+ concentrations, indicating that K+ regulates NLRP3 inflammasome activation [24]. P2X7, a kind of P2 receptors can be activated by ATP aggregation, which is required for ATP aggregation-induced activation of NLRP3 [25]. In recent years it has been found that P2X7 may partially regulate K+ currents through the two-pore domain K+ channels, such as Pore Domain Halothane-Inhibited Potassium Channel 1 (THIK-1) and Two-pore domain Weak Inwardly rectifying K+ channel 2 (TWIK-2) [26] (Fig. 3). In addition, the K+ efflux caused by some microbial toxins and the destruction of the cell membrane is also a pathway activating the NLRP3 inflammasome [27, 28]. According to recent studies, K+ efflux promotes the activation of the NLRP3 inflammasome through a mechanism that may be induced by mitochondrial damage and mitochondria ROS (mtROS) production [10, 29]. In addition, Yuhua Chen et al. reversed neuroinflammation caused by brain injury by knocking down NIMA-related kinase 7 (NEK7). This study further proved that NEK7 is useful as a modulator by regulating the interaction of NEK7–NLRP3, and thus the activation of the NLRP3 inflammasome is mediated by K+ efflux [12, 21, 30, 31]. Furthermore, the interaction between NLRP3-NEK7 may not be sufficient to activate NLRP3, which may also be required to convert a central nucleotide-binding and oligomerization from an inactive to an active conformation because of NLRP3 oligomerization. This conformational transition likely requires ATP binding and other unknown allosteric triggers [32] (Fig. 3).
Increased intracellular Ca2+ levels promote NLRP3 activation
As an indispensable second messenger in many cellular processes, Ca2+ plays an important role in the activation of the NLRP3 inflammasome. Extracellular ATP promotes Ca2+ influx through the P2X7 receptor, which induces the activation of the NLRP3 inflammasome, but this conclusion remains controversial and more evidence is needed to prove it [33,34,35]. Increasing levels of extracellular calcium ions stimulate G protein-coupled calcium-sensitive receptors to catalyze the production of inositol-1,4,5-triphosphate via phospholipase C, induce Ca2+ release from endoplasmic reticulum stores and then activate the NLRP3 inflammasome [36, 37]. Ca2+ influx induced by the membrane attack complex subsequently promotes the release of calcium stored in the endoplasmic reticulum by activating the ryanodine receptor (RyR) or inositol 1,4,5-trisphosphate receptor (IP3R), which will further increase the intracellular Ca2+ concentration and cause mitochondrial dysfunction through mitochondrial calcium transporters, promoting the activation of the NLRP3 inflammasome[38]. Hidenori Ichijo et al. found that the destruction of lysosomes regulates the activation of NLRP3 inflammasomes and promoting ASC oligomerization [39]. In addition, some inflammasome activators mediate IL-1β release by promoting the opening of a transient receptor potential (TRP) family of ion channels, including TRPM2, TRPM8, TRPM7, and TRPV2. The fluctuation of Ca2+ and Mg2+ concentrations promote the phosphorylation of TAK1, which in turn activates the NLRP3 inflammasome [13, 40, 41]. Importantly, studies have shown that excessive or sustained Ca 2+ uptake leads to mitochondrial damage characterized by increased mtROS production, a shift in mitochondrial permeability, and ultimately mitochondrial rupture, releasing mtROS and mitochondria DNA (mtDNA) into the cytoplasm, demonstrating that Ca 2 + Stimulation of mobilization leads to mitochondrial damage to activate the NLRP3 inflammasome, and mtROS is required for the NLRP3 inflammasome in response to LPS and ATP activation [42, 43] (Fig. 3). Most NLRP3 agonists can induce ROS production, a common signal of NLRP3 inflammasome activation [44, 45]. However, in-depth studies are needed to determine the role and mechanism of ROS on NLRP3 inflammasome activation.
Cl− efflux and NLRP3 inflammasome activation
Cl− efflux has been shown to be another regulatory pathway that regulates NLRP3 activation. A decrease in intracellular chloride ions promotes the ATP-induced processing and secretion of IL-1β [46]. Hypotonicity induces IL-1β release by activating the NLRP3 inflammasome; hypertonicity exerts its effect through the mechanism of regulatory cell volume reduction (RVD) achieved by reducing the concentrations of K+ and Cl− in the cell [47]. Significant cell expansion occurs in macrophages stimulated with LPS-ATP, and this response is controlled by the synergistic effects of K+ and Cl− [41]. The inhibitory effects of high concentrations of extracellular NaCl and chloride ion inhibitors also indicate that chloride plays a role in the activation of the NLRP3 inflammasome [48]. Recent studies have found that intracellular Cl– concentration at 75 mM indirectly regulates NLRP3 and the pyrin domain of caspase 1 (CASP1) with maximum expression and activity, as well as greater ROS activity, while PYD and CARD domain-containing (PYCARD/ASC)) expression remained constant from 0 to 125 mM Cl–. Cl– can stimulate the secretion of mature IL-1β through regulation, which in turn upregulates ROS, caspase-1, NLRP3 and IL-1β itself through autocrine signaling [49]. At the same time, a recent study determined that (leucine-rich repeat-containing protein 8A) LRRC8A, an important component of the volume-regulated anion channel (VRAC), is required for hypotonic induction of NLRP3 inflammasome activation. Therefore, other chloride channels also regulate the activation of the NLRP3 inflammasome [50]. In addition, CLIC1 and CLIC4, which are intracellular chloride channel proteins (CLICs), are involved in LPS-induced IL-1β activation and modulate NLRP3 activation [48]. CLIC-dependent chloride efflux is located downstream of the potassium efflux-mitochondrial ROS axis and alters the activation of the NLRP3 inflammasome by regulating the NEK7-NLRP3 interaction [29] (Fig. 3).
Na+ influx participates in NLRP3 activation
Na+ influx plays a role in NLRP3 activation, but it is not a necessary condition for NLRP3 activation (Fig. 2). In one study, gramicidin or other NLRP3 stimulators required a certain concentration of extracellular Na + to activate NLRP3. The authors found that this process also caused a decrease in K+ levels in the cell. Na+ influx may regulate NLRP3 activation by reducing the decrease in K+ in cells [24]. However, a large amount of Na+ released from mature endosomes and lysosomes induced by monosodium urate (MSU) crystals triggers the influx of water to reduce the intracellular K+ concentration rather than causing net cytoplasmic K+ loss [51]. In addition, the activation of the P2X7 receptor induced by the accumulation of large amounts of ATP promotes Na+ influx and subsequently induces the activation of the NLRP3 inflammasome [22]. Based on this evidence, Na+ influx exerts a certain effect on activating inflammasomes. However, the specific activation mechanism must be further clarified.
Intracellular pH and NLRP3 inflammasome activation
The dynamic balance of pH inside and outside the cell is necessary to maintain the various biochemical reactions in the cell, and a decrease in pH exerts a certain effect on promoting the occurrence of tissue inflammation. Under acidic conditions, the low pH induces NLRP3 activation and IL-1β release through the K+ efflux mechanism, as well as the secretion of active cathepsin B [52]. In addition, after the virus is engulfed by endosomes and enters the cell, it fuses to form a membrane pore in an acidic environment, which promotes virus replication, causes infection, and activates the inflammasome [53] (Fig. 2). It was recently found that in influenza A virus infection, the M2 proton channel protein is activated under acidic conditions of pH 6 and causes the fusion of the endosomal membrane and the viral membrane, resulting in the release of viral genetic material into the cytoplasm and regulation of Golgi dispersion, Recruitment and activation of the NLRP3 inflammasome leads to the production of IL-1β, which may be the induction of influenza A pathogenesis[54]. Furthermore, extracellular lactate was found to regulate intercellular reactive oxygen species (ROS) levels through proton-gated channel subfamilies acid-sensitive ion channel 1 (ASIC1) and ASIC3. ROS promotes NLRP3 inflammasome activation and IL-1β release by activating the NF-κB signaling pathway. Therefore, ASIC is expected to be a potential target for future treatment of NLRP3 inflammasome activation-related diseases [55] (Fig. 3).
Inflammasomes, ion channels and diseases
Parkinson's disease (PD)
Parkinson's disease is a neuroinflammatory disease characterized by loss of dopamine function. α-Synuclein (αSyn) in microglia mediates NLRP3 inflammasome activation to induce IL-1β secretion, and pyroptosis induced by αSyn damages dopamine neurons and causes Parkinson's disease [56, 57]. The ATP-sensitive K+ (K-ATP) channel is a member of the inward rectifying channels and consists of four pore-forming Kir6.x (Kir6.1 or Kir6.2) subunits and four regulatory sulfonate urea receptor (SUR1 or SUR2) subunits [58]. Studies have found that Kir6.1 (one of the ATP-sensitive potassium (K-ATP) channel subunits) deletion inhibits astrocyte phagocytosis by inducing mitochondrial dysfunction and mitochondrial ROS production, which contribute to the excessive activation of the NLRP3 inflammasome and the production of proinflammatory factors, thereby inducing the occurrence of PD. Thus, the Kir6.1/K-ATP channel expressed in astrocytes may be a target for preventing the degeneration of DA neurons in patients with PD and treating PD [59]. Besides, calcium ions released from the endoplasmic reticulum induce NLRP3 inflammasome assembly, as well as increased osmotic pressure in glial cells, active caspase-1 cleaves GSDMD to obtain GSDMD-CT (C-terminal fragment) and GSDMD-NT (N-terminal fragment), the latter one promotes the formation of membrane pores and regulate cell pyroptosis, thereby promoting neuroinflammation. Researchers found that THIK-1 is required for NLRP3-dependent Caspase-1 activation and IL-1β release in response to ATP. By blocking THIK-1, it inhibits the release of Pro-inflammatory cytokine il-1β from the activated microglia, which suggests that THIK-1 may be a therapeutic target for Nervous system inflammation diseases [26, 60].
Alzheimer's disease (AD)
The activation and aggregation of microglia induced by the deposition of the fibrillary peptide amyloid-β (Aβ) is a neuronal abnormality that is the basis of dementia and is an important pathological factor leading to the occurrence of Alzheimer's disease [57]. Aβ induces caspase-1 activation and the release of mature IL-1β by activating NLRP3, causing neuroinflammation and neurotoxicity [61]. The nonsteroidal anti-inflammatory drug fenamate inhibits the NLRP3 inflammasome by blocking a Cl− channel on the plasma membrane called the VRAC Ticagrelor (Table 1). This drug inhibits Alzheimer’s disease-related cognitive impairment in a rodent model, which provides an option for the treatment of NLRP3-related inflammatory diseases [62]. In addition, knockout of mouse microglia Na+-K+-2Cl− cotransporter (NKCC1) leads to the initiation of the NLRP3 inflammasome and increases the production of interleukin 1β (IL-1β), thereby predisposing microglia to excessive inflammatory response, showing significantly increased brain damage, inflammation, cerebral edema, and worse neurological outcomes [63]. This suggests that the Kir6.1/K-ATP and Na+-K+-2Cl− channel of astrocytes may be a target for preventing the degeneration of dopamine neurons in PD and treating PD.
Pneumonia
PM2.5 is a major factor affecting people's health due to urbanization. When PM2.5 enters the lungs from the respiratory tract, it may cause pneumonia, airway hyperresponsiveness and even asthma [64]. PM2.5 enters cells through a variety of phagocytosis processes and release cathepsin B to produce ROS and mediate K+ efflux, which in turn activate the NLRP3 inflammasome and eventually lead to lung inflammation and pulmonary fibrosis [65]. Similarly, in some experiments, an intranasal instillation of PM2.5 in mice caused lung inflammation, airway hyperresponsiveness, and oxidative stress in mice, because instilled PM2.5 increases the levels of H2O2 and mtROS and subsequently directly activates TRPV1 and TRPA1. Then, Ca2+ influx mediated by the opening of TRPV1 and TRPA1 activate the NLRP3 inflammasome, and the increase in mtROS levels also directly induces the activation of the NLRP3 inflammasome. The authors also found that the use of the TRPV1 antagonist AMG9810 and the TRPA1 antagonist A967079 alone or in combination alleviates pneumonia in mice induced by these processes. Inhibition of TRPA1 alone or TRPV1 and TRPA1 in combination may be more effective than inhibition of TRPV1 alone in treating PM2.5-induced lung injury [66]. Deletion of the Kcnk6 gene (encoding TWIK2) suppressed NLRP3 activation in macrophages and suppressed sepsis-induced lung inflammation. Adoptive transfer of Kcnk6−/− macrophages into the mouse airways after macrophage depletion also prevents inflammatory lung injury [21].
Heart failure
Studies have shown that the necrotic myocardium after myocardial infarction can act as DAMP to induce the assembly of NLRP3 inflammasome, causing cardiac inflammation and accelerating heart failure. Therefore, the targeted therapy of NLRP3 inflammasome may be a feasible strategy to reduce the area of myocardial infarction and prevent heart failure after acute myocardial infarction [67]. Some studies found that the upregulation of miR-144-3p significantly reduced myocardial ischemia/reperfusion injury (MIRI) in vivo and in vitro. They further proved that Ca2+-activated Cl− channels encoded by anoctamin-1 (ANO1) is the target gene of miR-144- 3p. Targeting miR-144-3p / ANO1 can inhibit the activation of NLRP3 inflammasome inflammatory signal in myocardial cells. It provides new insights for targeted therapy of myocardial ischemia [68]. Studies have shown that the overexpression of Ca2+ /calmodulin-dependent protein kinase IIδ (CMCaMKIIδ) can cause heart failure and contribute to the expression of inflammatory genes [69,70,71]. In recent years, based on the occurrence of arrhythmia and oxidative stress are all related to the increase of the concentration of Na+ and Ca2+ in myocardial cells. Long-term inhibition of Na+/H+ exchanger (NHE) can prevent or reduce heart failure [72]. A new antidiabetic drug empagliflzin, which is a selective inhibitor of renal proximal tubule sodium-dependent glucose transporter 2 (SGLT2), can inhibit cardiac NHE and reduce CaMKII activity and CaMKII-dependent sarcoplasmic reticulum calcium ion leakage. Thereby reduce cardiac cytoplasm [Na+] and [Ca2+] and increase cardiomyocyte mitochondria [Ca2+], which can inhibit the initiation and activation of NLRP3 inflammasome, thus have a direct anti-inflammatory effect on the heart and effectively improve the prognosis of heart failure in diabetic patients [73,74,75]. The study found that administration of MCC950, a specific NLRP3 inflammasome inhibitor, could inhibit the NLRP3 inflammasome by upregulating the expression of ion channel proteins (Kv4.2, KChIP2 and Cav1.2) in mice with heart failure, thereby improving the vulnerability of ventricular arrhythmias caused by heart failure [76]. In addition, chloride channel blockers can inhibit ROS-promoted CLIC-induced chloride plasma membrane translocation in cardiomyocytes and restore NLRP3-mediated cardiomyocyte pyroptosis [77]. In addition, ticagrelor is an oral P2Y12 receptor antagonist, which can rapidly and robustly inhibit the activation of NLRP3 inflammasome in peripheral blood mononuclear cells of patients with acute coronary syndrome by degrading chloride intracellular channel proteins (CLICs) and blocking the translocation of CLICs to the plasma membrane [78]. (Table 1).
Liver damage
Based on the role of NLRP3 in obesity-related metabolic syndrome, experiments have shown that saturated fatty acids activate the NLRP3 inflammasome by inducing the destruction of NKA caused by the accumulation of saturated phosphatidylcholine and the loss of plasma membrane fluidity. Therefore, cotreatment with unsaturated fatty acids may represent a new treatment approach for reducing obesity-related inflammation, such as nonalcoholic liver cirrhosis and insulin resistance [79]. K-ATP channels are involved in the regulation of many cellular activities as metabolic sensors [80]. The opening of the Kir6.2/K-ATP channel protects mice from liver damage caused by LPS-induced activation of the NLRP3 inflammasome, continuous high levels of IL1β, IL-18, and TNF-α and excessive endoplasmic reticulum stress and autophagy of liver cells. Therefore, the new K-ATP channel opener iptakalim may exert a potential therapeutic effect on protecting against liver injury [81]. In contrast, studies have shown that low-dose glibenclamide (a type 2 diabetes drug that inhibits K-ATP channels in pancreatic β cells) downregulates TGF-β1, NLRP3, ASC, TGF-β1, NLRP3, and ASC expression induced by thioacetamide (Table 1). The expression of caspase-1 and IL-1β and upregulation of catalase resist thioacetamide-induced liver damage, which exerts a certain protective effect on the liver. However, appropriate doses of this drug and in vitro and in vivo experiments are needed before future clinical applications [82]. In general, approaches targeting ion channels related to the activation of the NLRP3 inflammasome may provide new insights into the treatment of liver inflammation.
Rheumatoid arthritis (RA)
RA is a common chronic autoimmune disease that usually manifests as symmetrical and aggressive joint inflammation of multiple small joints. Studies have found that the NLRP3 inflammasome is highly activated in the synovium of patients with RA and collagen-induced rheumatoid arthritis model mice and that NLRP3 activation plays an important role in the pathogenesis of RA [83]. Researchers have found that the Ca2+-activated K+ channels KCa1.1 and KCa3.1 promote the occurrence of autoimmune diseases. One of the mechanisms underlying this event is the activation of NLRP3. Hydroxychloroquine HCQ, an ion channel inhibitor, inhibits the K+ channel activated by Ca2+, which is a strategy for the treatment of RA [84]. The expression of calcium-sensing receptor (CaSR) is increased in monocytes and locally damaged joints of patients with RA, and the activation of the NLRP3 inflammasome mediated by CaSR promotes the occurrence of RA. Therefore, inhibition of CaSR is also a strategy for the treatment of RA [85]. In addition, ASIC1a is an extracellular H+-activated cation channel that mainly affects the permeability of Na+ and Ca2+, which upregulate the NLRP3 inflammasome and the expression of proinflammatory factors to induce pyrolysis of chondrocytes in arthritic rats [86]. These discoveries provide a new direction for studying the mechanism of RA.
Kidney damage
Uric acid (UA) crystals are one factor stimulating NLRP3 activation. Soluble UA increases NLRP3 expression in proximal renal tubular epithelial cells in a TLR4-dependent manner and promotes caspase-1 activation and the production of IL-1β and intercellular adhesion molecule 1, ultimately inducing innate immunity in proximal tubular epithelial cells of the kidney [87]. High UA levels also induce NLRP3 activation through ROS activation and K+ efflux to cause vascular endothelial cell damage [88]. Investigators have shown that damage to the basolateral Na+–K+–ATPase (NKA) leads to protein tyrosine kinase binding and dissociation of NKA, leading to NLRP3 activation, IL-1β upregulation, and renal inflammation. In addition, the expression of NKAα1 significantly reduces UA-induced ROS generation and reduces early-onset apoptosis, but has no effect on late apoptosis. Reversing UA accumulation leads to a decrease in the mitochondrial membrane potential and reduces mitochondrial dysfunction [89]. Based on these results, NKA exerts a protective effect on kidney damage caused by UA and provides a new insight into strategies for protecting the kidney. Hyperhomocysteinemia (hHcy)-induced podocyte NLRP3 inflammasome activation is an initiating event in glomerulonephritis. Hcy inhibits the transient receptor potential mucolipin 1 (TRPML1) channel activity in lysosomes by enhancing ROS generated by NADPH oxidase, resulting in reduced lysosome-multivesicular bodies (MVB) interactions and more exosome release in podocytes. Exosome secretion may be the pathogenic mechanism mediating the release of inflammatory cytokines produced by the NLRP3 inflammasome in podocytes. Targeting the TRPML1 channel provides a new therapeutic strategy for attenuating podocyte-derived inflammatory exosome release and consequent glomerular inflammation [90].
Type 2 diabetes
Sufficient research evidence shows that type 2 diabetes is related to the chronic inflammatory response mediated by monocyte activation. In particular, IL-1β released by the activation of the NLRP3 inflammasome reduces tyrosine phosphorylation, and the negatively regulation of insulin receptor substrate 1 mRNA expression directly inhibits the insulin signaling pathway, leading to insulin resistance and type 2 diabetes mellitus (T2DM) [91, 92]. As mentioned above, K+ efflux and Na+ influx regulate the activation of the NLRP3 inflammasome. Similarly, experiments have shown that rats fed a high-salt diet exhibit increased oxidative stress followed by the activation of the NLRP3 inflammasome to induce insulin resistance, while potassium supplementation improves insulin resistance [93]. Thus, determining the role of NLRP3-activating related ion channels in the development of diabetes is important for improving insulin resistance. The K-ATP channel Kir6.1 is potentially useful as a negative regulator of the NLRP3 inflammasome and insulin resistance, and it is a very promising target for the treatment of diabetes [94] (Table 1). In addition, some experiments have found that hyperglycemia (30 mM glucose for 48 h) induces the activation of NADPH oxidase through TRPM2 channel-mediated Ca2+ influx in monocytes, which contributes to ROS generation and thioredoxin-interacting protein -mediated activation of the NLRP3 inflammasome. Thus, TRPM2 may represent a new target for ameliorating T2DM caused by hyperglycemia-induced oxidative stress and subsequent NLRP3 inflammasome activation [35]. Moreover, silencing the expression of the mitochondrial Na+/Ca2+ exchanger (NCLX) will hinder mitochondrial Ca2+ efflux that promotes ROS generation and mitochondrial damage, which finally results in the activation of endothelial cell apoptosis. Therefore, NCLX provides new insights into the mechanism of diabetic vascular disease and may also provide new strategies for the treatment of diabetes and its vascular complications [95].
Conclusions and prospects
The NLRP3 inflammasome plays an important role in the inflammatory response and immune defenses and is closely related to the occurrence and development of many diseases. The mechanism underlying inflammasome activation has always been the focus of discussion, and changes in the plasma contents of K+, Ca2+, and Cl− in cells are different cellular signals that modulate the activation of the NLRP3 inflammasome. In recent years, further studies have found that a variety of NLRP3 inflammasome activation-induced diseases involve different ion channels. Based on this knowledge, some treatment strategies have been proposed for diseases associated with abnormal activation of NLRP3. Although the mechanisms regulating these ions and the roles of ion channels are now understood, they are not comprehensive, the relationship between various ion signaling pathways is not sufficiently clear, and the other ion channels involved in NLRP3 inflammasome-induced diseases have not been sufficiently clarified. Therefore, more effort is needed to obtain additional information. For example, the unified activation pathway of NLRP3, calcium ion signaling between the endoplasmic reticulum and mitochondria, and the mechanism of ROS on NLRP3 inflammasome activation need to be further studied.
Data availability
Not applicable.
Abbreviations
- NLRP3:
-
Nod-like receptor protein 3
- PRRs:
-
Pattern-recognition receptors
- PAMPs:
-
Pathogen-associated molecular patterns
- DAMPs:
-
Danger-associated molecular patterns
- ASC:
-
Apoptosis-associated speck-like protein containing a caspase recruit domain
- TLRs:
-
Toll-like receptors
- LPS:
-
Lipopolysaccharide
- NF-κB:
-
Nuclear factor-kappa B
- PYD:
-
Pyrin domain
- CARD:
-
Caspase-activation and recruitment domain
- GSDMD:
-
Gasdermin D
- THIK-1:
-
Pore domain halothane-inhibited potassium channel 1
- TWIK-2:
-
Two-pore domain weak inwardly rectifying K+ channel 2
- NEK7:
-
NIMA-related kinase 7
- RyR:
-
Ryanodine receptor
- IP3R:
-
Inositol 1,4,5-trisphosphate receptor
- RVD:
-
Cell volume reduction
- VRAC:
-
Volume-regulated anion channel
- TRP:
-
Transient receptor potential
- mtROS:
-
Mitochondria ROS
- mtDNA:
-
Mitochondria DNA
- MSU:
-
Monosodium urate
- ASIC:
-
Acid-sensitive ion channel
- PD:
-
Parkinson's disease
- K-ATP channel:
-
ATP-sensitive K + channel
- SUR:
-
Sulfonate urea receptor
- AD:
-
Alzheimer's disease
- Aβ:
-
Amyloid-β
- ANO1:
-
Ca2+-activated Cl− channels encoded by anoctamin-1
- NHE:
-
Na+/H+ exchanger
- RA:
-
Rheumatoid arthritis
- CaSR:
-
Calcium-sensing receptor
- SGLT2:
-
Sodium-dependent glucose transporter 2
- UA:
-
Uric acid
- NKA:
-
Na+–K+–ATPase
- T2DM:
-
Type 2 diabetes mellitus
- NCLX:
-
Na+/Ca2+ exchanger
- CASP1:
-
Caspase 1
References
Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10:417–426. https://doi.org/10.1016/s1097-2765(02)00599-3
Zheng D, Liwinski T, Elinav E (2020) Inflammasome activation and regulation: toward a better understanding of complex mechanisms. Cell Discov 6:36. https://doi.org/10.1038/s41421-020-0167-x
Kelley N, Jeltema D, Duan Y, He Y (2019) The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. https://doi.org/10.3390/ijms20133328
Chauhan D, Vande Walle L, Lamkanfi M (2020) Therapeutic modulation of inflammasome pathways. Immunol Rev 297:123–138. https://doi.org/10.1111/imr.12908
Zhou CB, Fang JY (2019) The role of pyroptosis in gastrointestinal cancer and immune responses to intestinal microbial infection. Biochim Biophys Acta Rev Cancer 1872:1–10. https://doi.org/10.1016/j.bbcan.2019.05.001
Moossavi M, Parsamanesh N, Bahrami A, Atkin SL, Sahebkar A (2018) Role of the NLRP3 inflammasome in cancer. Mol Cancer 17:158. https://doi.org/10.1186/s12943-018-0900-3
Malik A, Kanneganti TD (2017) Inflammasome activation and assembly at a glance. J Cell Sci 130:3955–3963. https://doi.org/10.1242/jcs.207365
Wang L, Hauenstein AV (2020) The NLRP3 inflammasome: mechanism of action, role in disease and therapies. Mol Aspects Med 76:100889. https://doi.org/10.1016/j.mam.2020.100889
Mangan MSJ, Olhava EJ, Roush WR, Seidel HM, Glick GD, Latz E (2018) Targeting the NLRP3 inflammasome in inflammatory diseases. Nat Rev Drug Discov 17:588–606. https://doi.org/10.1038/nrd.2018.97
Gong T, Yang Y, Jin T, Jiang W, Zhou R (2018) Orchestration of NLRP3 inflammasome activation by ion fluxes. Trends Immunol 39:393–406. https://doi.org/10.1016/j.it.2018.01.009
Hafner-Bratkovič I, Pelegrín P (2018) Ion homeostasis and ion channels in NLRP3 inflammasome activation and regulation. Curr Opin Immunol 52:8–17. https://doi.org/10.1016/j.coi.2018.03.010
Zhao N, Li CC, Di B, Xu LL (2020) Recent advances in the NEK7-licensed NLRP3 inflammasome activation: mechanisms, role in diseases and related inhibitors. J Autoimmun 113:102515. https://doi.org/10.1016/j.jaut.2020.102515
Wang L, Negro R, Wu H (2020) TRPM2, linking oxidative stress and Ca(2+) permeation to NLRP3 inflammasome activation. Curr Opin Immunol 62:131–135. https://doi.org/10.1016/j.coi.2020.01.005
Boucher D, Monteleone M, Coll RC, Chen KW, Ross CM, Teo JL, Gomez GA, Holley CL, Bierschenk D, Stacey KJ, Yap AS, Bezbradica JS, Schroder K (2018) Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity. J Exp Med 215:827–840. https://doi.org/10.1084/jem.20172222
Schroder K, Tschopp J (2010) The inflammasomes. Cell 140:821–832. https://doi.org/10.1016/j.cell.2010.01.040
Vanaja SK, Rathinam VA, Fitzgerald KA (2015) Mechanisms of inflammasome activation: recent advances and novel insights. Trends Cell Biol 25:308–315. https://doi.org/10.1016/j.tcb.2014.12.009
Kayagaki N, Stowe IB, Lee BL, O’Rourke K, Anderson K, Warming S, Cuellar T, Haley B, Roose-Girma M, Phung QT, Liu PS, Lill JR, Li H, Wu J, Kummerfeld S, Zhang J, Lee WP, Snipas SJ, Salvesen GS, Morris LX, Fitzgerald L, Zhang Y, Bertram EM, Goodnow CC, Dixit VM (2015) Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 526:666–671. https://doi.org/10.1038/nature15541
Shi J, Zhao Y, Wang Y, Gao W, Ding J, Li P, Hu L, Shao F (2014) Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 514:187–192. https://doi.org/10.1038/nature13683
Pelegrin P, Surprenant A (2006) Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. Embo j 25:5071–5082. https://doi.org/10.1038/sj.emboj.7601378
Gaidt MM, Ebert TS, Chauhan D, Schmidt T, Schmid-Burgk JL, Rapino F, Robertson AA, Cooper MA, Graf T, Hornung V (2016) Human monocytes engage an alternative inflammasome pathway. Immunity 44:833–846. https://doi.org/10.1016/j.immuni.2016.01.012
Di A, Xiong S, Ye Z, Malireddi RKS, Kometani S, Zhong M, Mittal M, Hong Z, Kanneganti TD, Rehman J, Malik AB (2018) The TWIK2 potassium efflux channel in macrophages mediates NLRP3 inflammasome-induced inflammation. Immunity 49:56-65.e4. https://doi.org/10.1016/j.immuni.2018.04.032
Karmakar M, Katsnelson MA, Dubyak GR, Pearlman E (2016) Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1beta secretion in response to ATP. Nat Commun 7:10555. https://doi.org/10.1038/ncomms10555
Pétrilli V, Papin S, Dostert C, Mayor A, Martinon F, Tschopp J (2007) Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 14:1583–1589. https://doi.org/10.1038/sj.cdd.4402195
Munoz-Planillo R, Kuffa P, Martinez-Colon G, Smith BL, Rajendiran TM, Nunez G (2013) K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 38:1142–1153. https://doi.org/10.1016/j.immuni.2013.05.016
Wang W, Hu D, Feng Y, Wu C, Song Y, Liu W, Li A, Wang Y, Chen K, Tian M, Xiao F, Zhang Q, Chen W, Pan P, Wan P, Liu Y, Lan H, Wu K, Wu J (2020) Paxillin mediates ATP-induced activation of P2X7 receptor and NLRP3 inflammasome. BMC Biol 18:182. https://doi.org/10.1186/s12915-020-00918-w
Drinkall S, Lawrence CB, Ossola B, Russell S, Bender C, Brice NB, Dawson LA, Harte M, Brough D (2022) The two pore potassium channel THIK-1 regulates NLRP3 inflammasome activation. Glia 70:1301–1316. https://doi.org/10.1002/glia.24174
Hamon MA, Cossart P (2011) K+ efflux is required for histone H3 dephosphorylation by Listeria monocytogenes listeriolysin O and other pore-forming toxins. Infect Immun 79:2839–2846. https://doi.org/10.1128/iai.01243-10
Suresh R, Chandrasekaran P, Sutterwala FS, Mosser DM (2016) Complement-mediated “bystander” damage initiates host NLRP3 inflammasome activation. J Cell Sci 129:1928–1939. https://doi.org/10.1242/jcs.179291
Tang T, Lang X, Xu C, Wang X, Gong T, Yang Y, Cui J, Bai L, Wang J, Jiang W, Zhou R (2017) CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation. Nat Commun 8:202. https://doi.org/10.1038/s41467-017-00227-x
Shi H, Wang Y, Li X, Zhan X, Tang M, Fina M, Su L, Pratt D, Bu CH, Hildebrand S, Lyon S, Scott L, Quan J, Sun Q, Russell J, Arnett S, Jurek P, Chen D, Kravchenko VV, Mathison JC, Moresco EM, Monson NL, Ulevitch RJ, Beutler B (2016) NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component. Nat Immunol 17:250–258. https://doi.org/10.1038/ni.3333
He Y, Zeng MY, Yang D, Motro B, Núñez G (2016) NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature 530:354–357. https://doi.org/10.1038/nature16959
Sharif H, Wang L, Wang WL, Magupalli VG, Andreeva L, Qiao Q, Hauenstein AV, Wu Z, Núñez G, Mao Y, Wu H (2019) Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome. Nature 570:338–343. https://doi.org/10.1038/s41586-019-1295-z
Gilbert DF, Stebbing MJ, Kuenzel K, Murphy RM, Zacharewicz E, Buttgereit A, Stokes L, Adams DJ, Friedrich O (2016) Store-operated Ca(2+) entry (SOCE) and purinergic receptor-mediated Ca(2+) homeostasis in murine bv2 microglia cells: early cellular responses to ATP-mediated microglia activation. Front Mol Neurosci 9:111. https://doi.org/10.3389/fnmol.2016.00111
Yabal M, Calleja DJ, Simpson DS, Lawlor KE (2019) Stressing out the mitochondria: mechanistic insights into NLRP3 inflammasome activation. J Leukoc Biol 105:377–399. https://doi.org/10.1002/jlb.Mr0318-124r
Tseng HH, Vong CT, Kwan YW, Lee SM, Hoi MP (2016) TRPM2 regulates TXNIP-mediated NLRP3 inflammasome activation via interaction with p47 phox under high glucose in human monocytic cells. Sci Rep 6:35016. https://doi.org/10.1038/srep35016
Lee GS, Subramanian N, Kim AI, Aksentijevich I, Goldbach-Mansky R, Sacks DB, Germain RN, Kastner DL, Chae JJ (2012) The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature 492:123–127. https://doi.org/10.1038/nature11588
Rossol M, Pierer M, Raulien N, Quandt D, Meusch U, Rothe K, Schubert K, Schöneberg T, Schaefer M, Krügel U, Smajilovic S, Bräuner-Osborne H, Baerwald C, Wagner U (2012) Extracellular Ca2+ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors. Nat Commun 3:1329. https://doi.org/10.1038/ncomms2339
Triantafilou K, Hughes TR, Triantafilou M, Morgan BP (2013) The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation. J Cell Sci 126:2903–2913. https://doi.org/10.1242/jcs.124388
Okada M, Matsuzawa A, Yoshimura A, Ichijo H (2014) The lysosome rupture-activated TAK1-JNK pathway regulates NLRP3 inflammasome activation. J Biol Chem 289:32926–32936. https://doi.org/10.1074/jbc.M114.579961
Santoni G, Cardinali C, Morelli MB, Santoni M, Nabissi M, Amantini C (2015) Danger- and pathogen-associated molecular patterns recognition by pattern-recognition receptors and ion channels of the transient receptor potential family triggers the inflammasome activation in immune cells and sensory neurons. J Neuroinflammation 12:21. https://doi.org/10.1186/s12974-015-0239-2
Yang L, Zhu L, Xu Y, Zhang H, Ye W, Mao J, Chen L, Wang L (2012) Uncoupling of K+ and Cl- transport across the cell membrane in the process of regulatory volume decrease. Biochem Pharmacol 84:292–302. https://doi.org/10.1016/j.bcp.2012.05.006
Murakami T, Ockinger J, Yu J, Byles V, McColl A, Hofer AM, Horng T (2012) Critical role for calcium mobilization in activation of the NLRP3 inflammasome. Proc Natl Acad Sci U S A 109:11282–11287. https://doi.org/10.1073/pnas.1117765109
Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, Lam HC, Englert JA, Rabinovitch M, Cernadas M, Kim HP, Fitzgerald KA, Ryter SW, Choi AM (2011) Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 12:222–230. https://doi.org/10.1038/ni.1980
Minutoli L, Puzzolo D, Rinaldi M, Irrera N, Marini H, Arcoraci V, Bitto A, Crea G, Pisani A, Squadrito F, Trichilo V, Bruschetta D, Micali A, Altavilla D (2016) ROS-mediated NLRP3 inflammasome activation in brain, heart, kidney, and testis ischemia/reperfusion injury. Oxid Med Cell Longev 2016:2183026. https://doi.org/10.1155/2016/2183026
Lin Q, Li S, Jiang N, Shao X, Zhang M, Jin H, Zhang Z, Shen J, Zhou Y, Zhou W, Gu L, Lu R, Ni Z (2019) PINK1-parkin pathway of mitophagy protects against contrast-induced acute kidney injury via decreasing mitochondrial ROS and NLRP3 inflammasome activation. Redox Biol 26:101254. https://doi.org/10.1016/j.redox.2019.101254
Verhoef PA, Kertesy SB, Lundberg K, Kahlenberg JM, Dubyak GR (2005) Inhibitory effects of chloride on the activation of caspase-1, IL-1beta secretion, and cytolysis by the P2X7 receptor. J Immunol 175:7623–7634. https://doi.org/10.4049/jimmunol.175.11.7623
Compan V, Baroja-Mazo A, Lopez-Castejon G, Gomez AI, Martinez CM, Angosto D, Montero MT, Herranz AS, Bazan E, Reimers D, Mulero V, Pelegrin P (2012) Cell volume regulation modulates NLRP3 inflammasome activation. Immunity 37:487–500. https://doi.org/10.1016/j.immuni.2012.06.013
Domingo-Fernandez R, Coll RC, Kearney J, Breit S, O’Neill LAJ (2017) The intracellular chloride channel proteins CLIC1 and CLIC4 induce IL-1beta transcription and activate the NLRP3 inflammasome. J Biol Chem 292:12077–12087. https://doi.org/10.1074/jbc.M117.797126
Clauzure M, Valdivieso ÁG, Dugour AV, Mori C, Massip-Copiz MM, Aguilar M, Sotomayor V, Asensio CJA, Figueroa JM, Santa-Coloma TA (2021) NLR family pyrin domain containing 3 (NLRP3) and caspase 1 (CASP1) modulation by intracellular Cl(-) concentration. Immunology 163:493–511. https://doi.org/10.1111/imm.13336
Green JP, Swanton T, Morris LV, El-Sharkawy LY, Cook J, Yu S, Beswick J, Adamson AD, Humphreys NE, Bryce R, Freeman S, Lawrence C, Brough D (2020) LRRC8A is essential for hypotonicity-, but not for DAMP-induced NLRP3 inflammasome activation. Elife. https://doi.org/10.7554/eLife.59704
Schorn C, Frey B, Lauber K, Janko C, Strysio M, Keppeler H, Gaipl US, Voll RE, Springer E, Munoz LE, Schett G, Herrmann M (2011) Sodium overload and water influx activate the NALP3 inflammasome. J Biol Chem 286:35–41. https://doi.org/10.1074/jbc.M110.139048
Rajamäki K, Nordström T, Nurmi K, Åkerman KE, Kovanen PT, Öörni K, Eklund KK (2013) Extracellular acidosis is a novel danger signal alerting innate immunity via the NLRP3 inflammasome. J Biol Chem 288:13410–13419. https://doi.org/10.1074/jbc.M112.426254
Cohen FS (2016) How viruses invade cells. Biophys J 110:1028–1032. https://doi.org/10.1016/j.bpj.2016.02.006
Pandey KP, Zhou Y (2022) Influenza a virus infection activates NLRP3 inflammasome through trans-golgi network dispersion. Viruses. https://doi.org/10.3390/v14010088
Zhao K, An R, Xiang Q, Li G, Wang K, Song Y, Liao Z, Li S, Hua W, Feng X, Wu X, Zhang Y, Das A, Yang C (2021) Acid-sensing ion channels regulate nucleus pulposus cell inflammation and pyroptosis via the NLRP3 inflammasome in intervertebral disc degeneration. Cell Prolif 54:e12941. https://doi.org/10.1111/cpr.12941
Wang S, Yuan YH, Chen NH, Wang HB (2019) The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson’s disease. Int Immunopharmacol 67:458–464. https://doi.org/10.1016/j.intimp.2018.12.019
Gordon R, Albornoz EA, Christie DC, Langley MR, Kumar V, Mantovani S, Robertson AAB, Butler MS, Rowe DB, O’Neill LA, Kanthasamy AG, Schroder K, Cooper MA, Woodruff TM (2018) Inflammasome inhibition prevents alpha-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aah4066
Gordon R, Albornoz EA, Christie DC, Langley MR, Kumar V, Mantovani S, Robertson AAB, Butler MS, Rowe DB, O’Neill LA, Kanthasamy AG, Schroder K, Cooper MA, Woodruff TM (2018) Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aah4066
Hu ZL, Sun T, Lu M, Ding JH, Du RH, Hu G (2019) Kir6.1/K-ATP channel on astrocytes protects against dopaminergic neurodegeneration in the MPTP mouse model of Parkinson’s disease via promoting mitophagy. Brain Behav Immun 81:509–522. https://doi.org/10.1016/j.bbi.2019.07.009
Madry C, Kyrargyri V, Arancibia-Cárcamo IL, Jolivet R, Kohsaka S, Bryan RM, Attwell D (2018) Microglial ramification, surveillance, and interleukin-1β release are regulated by the two-pore domain K(+) channel THIK-1. Neuron 97:299-312.e6. https://doi.org/10.1016/j.neuron.2017.12.002
Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz E, Moore KJ, Golenbock DT (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9:857–865. https://doi.org/10.1038/ni.1636
Daniels MJ, Rivers-Auty J, Schilling T, Spencer NG, Watremez W, Fasolino V, Booth SJ, White CS, Baldwin AG, Freeman S, Wong R, Latta C, Yu S, Jackson J, Fischer N, Koziel V, Pillot T, Bagnall J, Allan SM, Paszek P, Galea J, Harte MK, Eder C, Lawrence CB, Brough D (2016) Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer’s disease in rodent models. Nat Commun 7:12504. https://doi.org/10.1038/ncomms12504
Tóth K, Lénárt N, Berki P, Fekete R, Szabadits E, Pósfai B, Cserép C, Alatshan A, Benkő S, Kiss D, Hübner CA, Gulyás A, Kaila K, Környei Z, Dénes Á (2022) The NKCC1 ion transporter modulates microglial phenotype and inflammatory response to brain injury in a cell-autonomous manner. PLoS Biol 20:e3001526. https://doi.org/10.1371/journal.pbio.3001526
Ogino K, Nagaoka K, Okuda T, Oka A, Kubo M, Eguchi E, Fujikura Y (2017) PM2.5-induced airway inflammation and hyperresponsiveness in NC/Nga mice. Environ Toxicol 32:1047–1054. https://doi.org/10.1002/tox.22303
Zheng R, Tao L, Jian H, Chang Y, Cheng Y, Feng Y, Zhang H (2018) NLRP3 inflammasome activation and lung fibrosis caused by airborne fine particulate matter. Ecotoxicol Environ Saf 163:612–619. https://doi.org/10.1016/j.ecoenv.2018.07.076
Xu M, Zhang Y, Wang M, Zhang H, Chen Y, Adcock IM, Chung KF, Mo J, Zhang Y, Li F (2019) TRPV1 and TRPA1 in lung inflammation and airway hyperresponsiveness induced by fine particulate matter (PM2.5). Oxid Med Cell Longev 2019:7450151
Toldo S, Abbate A (2018) The NLRP3 inflammasome in acute myocardial infarction. Nat Rev Cardiol 15:203–214. https://doi.org/10.1038/nrcardio.2017.161
Yang G, Tang X, Tan L, Nong D, Yang P, Ning H (2021) Upregulation of miR-144-3p protects myocardial function from ischemia-reperfusion injury through inhibition of TMEM16A Ca(2+)-activated chloride channel. Hum Cell 34:360–371. https://doi.org/10.1007/s13577-020-00482-z
Suetomi T, Willeford A, Brand CS, Cho Y, Ross RS, Miyamoto S, Brown JH (2018) Inflammation and NLRP3 inflammasome activation initiated in response to pressure overload by Ca(2+)/calmodulin-dependent protein kinase II delta signaling in cardiomyocytes are essential for adverse cardiac remodeling. Circulation 138:2530–2544. https://doi.org/10.1161/CIRCULATIONAHA.118.034621
Dewenter M, Neef S, Vettel C, Lammle S, Beushausen C, Zelarayan LC, Katz S, von der Lieth A, Meyer-Roxlau S, Weber S, Wieland T, Sossalla S, Backs J, Brown JH, Maier LS, El-Armouche A (2017) Calcium/calmodulin-dependent protein kinase II activity persists during chronic beta-adrenoceptor blockade in experimental and human heart failure. Circ Heart Fail 10:e003840. https://doi.org/10.1161/CIRCHEARTFAILURE.117.003840
Weinreuter M, Kreusser MM, Beckendorf J, Schreiter FC, Leuschner F, Lehmann LH, Hofmann KP, Rostosky JS, Diemert N, Xu C, Volz HC, Jungmann A, Nickel A, Sticht C, Gretz N, Maack C, Schneider MD, Gröne HJ, Müller OJ, Katus HA, Backs J (2014) CaM Kinase II mediates maladaptive post-infarct remodeling and pro-inflammatory chemoattractant signaling but not acute myocardial ischemia/reperfusion injury. EMBO Mol Med 6:1231–1245
Baartscheer A (2003) Increased Na+/H+-exchange activity is the cause of increased [Na+]i and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure model. Cardiovasc Res 57:1015–1024. https://doi.org/10.1016/s0008-6363(02)00809-x
Byrne NJ, Matsumura N, Maayah ZH, Ferdaoussi M, Takahara S, Darwesh AM, Levasseur JL, Jahng JWS, Vos D, Parajuli N, El-Kadi AOS, Braam B, Young ME, Verma S, Light PE, Sweeney G, Seubert JM, Dyck JRB (2020) Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure. Circ Heart Fail 13:e006277. https://doi.org/10.1161/circheartfailure.119.006277
Mustroph J, Wagemann O, Lücht CM, Trum M, Hammer KP, Sag CM, Lebek S, Tarnowski D, Reinders J, Perbellini F, Terracciano C, Schmid C, Schopka S, Hilker M, Zausig Y, Pabel S, Sossalla ST, Schweda F, Maier LS, Wagner S (2018) Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes. ESC Heart Fail 5:642–648. https://doi.org/10.1002/ehf2.12336
Baartscheer A, Schumacher CA, Wüst RC, Fiolet JW, Stienen GJ, Coronel R, Zuurbier CJ (2017) Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)/H(+) exchanger in rats and rabbits. Diabetologia 60:568–573. https://doi.org/10.1007/s00125-016-4134-x
Jiang X, Yang F, Ou D, Huang L, Li H, Lang M (2022) MCC950 ameliorates ventricular arrhythmia vulnerability induced by heart failure. Bioengineered 13:8593–8604. https://doi.org/10.1080/21655979.2022.2053813
Li S, Dong S, Shi B, Xu Q, Li L, Wang S, Zhang W, Zhong M, Zhu J, Cheng Y, Zhang G, Hu S (2022) Attenuation of ROS/chloride efflux-mediated NLRP3 inflammasome activation contributes to alleviation of diabetic cardiomyopathy in rats after sleeve gastrectomy. Oxid Med Cell Longev 2022:4608914. https://doi.org/10.1155/2022/4608914
Huang B, Qian Y, Xie S, Ye X, Chen H, Chen Z, Zhang L, Xu J, Hu H, Ma S, Héroux P, Wang D, Shen HM, Wu Y, Xia D (2021) Ticagrelor inhibits the NLRP3 inflammasome to protect against inflammatory disease independent of the P2Y(12) signaling pathway. Cell Mol Immunol 18:1278–1289. https://doi.org/10.1038/s41423-020-0444-5
Gianfrancesco MA, Dehairs J, L’Homme L, Herinckx G, Esser N, Jansen O, Habraken Y, Lassence C, Swinnen JV, Rider MH, Piette J, Paquot N, Legrand-Poels S (2019) Saturated fatty acids induce NLRP3 activation in human macrophages through K(+) efflux resulting from phospholipid saturation and Na, K-ATPase disruption. Biochim Biophys Acta Mol Cell Biol Lipids 1864:1017–1030. https://doi.org/10.1016/j.bbalip.2019.04.001
Tinker A, Aziz Q, Li Y, Specterman M (2018) ATP-sensitive potassium channels and their physiological and pathophysiological roles. Compr Physiol 8:1463–1511. https://doi.org/10.1002/cphy.c170048
Du RH, Tan J, Yan N, Wang L, Qiao C, Ding JH, Lu M, Hu G (2014) Kir6.2 knockout aggravates lipopolysaccharide-induced mouse liver injury via enhancing NLRP3 inflammasome activation. J Gastroenterol 49:727–736. https://doi.org/10.1007/s00535-013-0823-0
Dwivedi DK, Jena GB (2018) Glibenclamide protects against thioacetamide-induced hepatic damage in Wistar rat: investigation on NLRP3, MMP-2, and stellate cell activation. Naunyn Schmiedebergs Arch Pharmacol 391:1257–1274. https://doi.org/10.1007/s00210-018-1540-2
Guo C, Fu R, Wang S, Huang Y, Li X, Zhou M, Zhao J, Yang N (2018) NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis. Clin Exp Immunol 194:231–243. https://doi.org/10.1111/cei.13167
Eugenia Schroeder M, Russo S, Costa C, Hori J, Tiscornia I, Bollati-Fogolín M, Zamboni DS, Ferreira G, Cairoli E, Hill M (2017) Pro-inflammatory Ca(++)-activated K(+) channels are inhibited by hydroxychloroquine. Sci Rep 7:1892. https://doi.org/10.1038/s41598-017-01836-8
Jäger E, Murthy S, Schmidt C, Hahn M, Strobel S, Peters A, Stäubert C, Sungur P, Venus T, Geisler M, Radusheva V, Raps S, Rothe K, Scholz R, Jung S, Wagner S, Pierer M, Seifert O, Chang W, Estrela-Lopis I, Raulien N, Krohn K, Sträter N, Hoeppener S, Schöneberg T, Rossol M, Wagner U (2020) Calcium-sensing receptor-mediated NLRP3 inflammasome response to calciprotein particles drives inflammation in rheumatoid arthritis. Nat Commun 11:4243. https://doi.org/10.1038/s41467-020-17749-6
Wu X, Ren G, Zhou R, Ge J, Chen FH (2019) The role of Ca(2+) in acid-sensing ion channel 1a-mediated chondrocyte pyroptosis in rat adjuvant arthritis. Lab Invest 99:499–513. https://doi.org/10.1038/s41374-018-0135-3
Xiao J, Zhang XL, Fu C, Han R, Chen W, Lu Y, Ye Z (2015) Soluble uric acid increases NALP3 inflammasome and interleukin-1beta expression in human primary renal proximal tubule epithelial cells through the Toll-like receptor 4-mediated pathway. Int J Mol Med 35:1347–1354. https://doi.org/10.3892/ijmm.2015.2148
Yin W, Zhou QL, OuYang SX, Chen Y, Gong YT, Liang YM (2019) Uric acid regulates NLRP3/IL-1beta signaling pathway and further induces vascular endothelial cells injury in early CKD through ROS activation and K(+) efflux. BMC Nephrol 20:319. https://doi.org/10.1186/s12882-019-1506-8
Xiao J, Zhang X, Fu C, Yang Q, Xie Y, Zhang Z, Ye Z (2018) Impaired Na(+)-K(+)-ATPase signaling in renal proximal tubule contributes to hyperuricemia-induced renal tubular injury. Exp Mol Med 50:e452. https://doi.org/10.1038/emm.2017.287
Li G, Huang D, Li N, Ritter JK, Li PL (2021) Regulation of TRPML1 channel activity and inflammatory exosome release by endogenously produced reactive oxygen species in mouse podocytes. Redox Biol 43:102013. https://doi.org/10.1016/j.redox.2021.102013
Ding S, Xu S, Ma Y, Liu G, Jang H, Fang J (2019) Modulatory mechanisms of the NLRP3 inflammasomes in diabetes. Biomolecules. https://doi.org/10.3390/biom9120850
Lontchi-Yimagou E, Sobngwi E, Matsha TE, Kengne AP (2013) Diabetes mellitus and inflammation. Curr Diab Rep 13:435–444. https://doi.org/10.1007/s11892-013-0375-y
Wan Z, Wen W, Ren K, Zhou D, Liu J, Wu Y, Zhou J, Mu J, Yuan Z (2018) Involvement of NLRP3 inflammasome in the impacts of sodium and potassium on insulin resistance in normotensive Asians. Br J Nutr 119:228–237. https://doi.org/10.1017/s0007114517002926
Du RH, Lu M, Wang C, Ding JH, Wu G, Hu G (2019) The pore-forming subunit Kir6.1 of the K-ATP channel negatively regulates the NLRP3 inflammasome to control insulin resistance by interacting with NLRP3. Exp Mol Med 51:1–13. https://doi.org/10.1038/s12276-019-0291-6
Zu Y, Wan LJ, Cui SY, Gong YP, Li CL (2015) The mitochondrial Na(+)/Ca(2+) exchanger may reduce high glucose-induced oxidative stress and nucleotide-binding oligomerization domain receptor 3 inflammasome activation in endothelial cells. J Geriatr Cardiol 12:270–278
Acknowledgements
We also thank Professor Biguang Tuo (Department of Gastroenterology, Affiliated Hospital to Zunyi Medical University) for highly professional services. This work was supported by Chinese Ministry of Education (2020-39).
Funding
This study was supported by research grants the National Natural Science Foundation of China (Nos. 82170628, 81970541, 31960151, 32160208), the Guizhou Provincial Department of Science and Technology Excellent Youth Project ([2021]5647), the Collaborative Innovation Center of Chinese Ministry of Education (2020-39) and the Basic Research Key Program of Guizhou Province (ZK [2021] key 004), the Guizhou Graduate Research Fund (No. YJSKYJJ (2021) 177).
Author information
Authors and Affiliations
Contributions
XLX and XLW wrote the manuscript. GYY, QMA, JL, XXY, ZJ, JHD, YXH and QD, collect the literature and collated materials. JYX and RX revised the manuscript for clarity and style. RX primarily revised and finalized manuscript. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
The authors have no competing interests to declare.
Consent for publication
We obtained consent to publish this paper from all participants of this study.
Ethical approval and consent to participate
No ethical approval was required for this review because it did not involve patients or patient data.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Xu, X., Wu, X., Yue, G. et al. The role of Nod-like receptor protein 3 inflammasome activated by ion channels in multiple diseases. Mol Cell Biochem 478, 1397–1410 (2023). https://doi.org/10.1007/s11010-022-04602-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-022-04602-1